Progression of Cardiovascular Disease in Type 1 Diabetes

The summary for the Progression of Cardiovascular Disease in Type 1 Diabetes grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Progression of Cardiovascular Disease in Type 1 Diabetes: The National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Diabetes, Digestive and Kidney diseases (NIDDK) invite investigator initiated applications for basic and clinical studies to enhance our understanding of the onset and progression of cardiovascular disease (CVD) in patients with type 1 diabetes. Classic CVD risk factors such as hyperglycemia, hypertension, dyslipidemia, and central obesity increase the risk of CVD in patients with type 1 diabetes, but do not fully explain the significantly higher incidence of CVD in type 1 diabetes. Thus type 1 diabetes may lead to unique mechanisms for the onset and progression of CVD, as well as influencing mechanisms known for type 2 diabetes and the general population. Identification of the mechanisms that trigger early development of atherosclerosis in type 1 diabetes is important for development of interventions to prevent and treat CVD in this population. This Request for Applications (RFA) seeks basic and clinical studies that will enhance our understanding of the effects of type 1 diabetes and its metabolic complications on the early development and fast progression of cardiovascular disease in these patients.
Federal Grant Title: Progression of Cardiovascular Disease in Type 1 Diabetes
Federal Agency Name: National Institutes of Health
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-HL-04-013
Type of Funding: Grant
CFDA Numbers: 93.83793.847
CFDA Descriptions: Heart and Vascular Diseases Research 93.847 Diabetes, Endocrinology and Metabolism Research
Current Application Deadline: No deadline provided
Original Application Deadline: Mar 24, 2004
Posted Date: Dec 08, 2003
Creation Date: Apr 23, 2004
Archive Date: Apr 23, 2004
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
State governments County governments City or township governments Special district governments Independent school districts Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education For profit organizations other than small businesses Small businesses Others (see text field entitled "Additional Information on Eligibility" for clarification)
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster FBOWebmaster@OD.NIH.GOV NIH OER Webmaster
More Grants from the National Institutes of Health
Ethical Issues in Translational Science Research (R01 Clinical Trial Optional)
A Collaborative Network to Optimize Emergency Care of Older Adults with Alzheimers Disease...
Innovations to Foster Healthy Longevity in Low-Income Settings (R03 Clinical Trial Not All...
HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Instit...
National Dental Practice-Based Research Network Clinical Trial or Observational Study Plan... is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2020